Figure 1 - uploaded by Bhuvan Nagpal
Content may be subject to copyright.
Source publication
The proliferative disorders of lymphoid cells may be reactive or neoplastic. Among the neoplastic lymphoid diseases, the distinction between leukemias and lymphomas is merely in the general tissue distribution of the disease with varying and mixed presentations at times. The broad group of lymphomas has been segregated into two types – Hodgkin’s an...
Similar publications
Unlike non-Hodgkin's lymphoma, central nervous system involvement with classical Hodgkin's lymphoma is exceedingly rare, thus information regarding treatment and prognostication of the disease is lacking. We present the case of a 47 year old female who presented with a left parietal dural-based lesion which proved to be Stage IE primary CNS classic...
Background: Treatment after failure of 2nd line chemotherapy in patients with Hodgkin's lymphoma (HL) or aggressive non-Hodgkin’s lymphoma (NHL) is not well studied. Aim: To assess the value of 3rd line treatment in a cohort of HL and aggressive NHL patients. Methods: This was a retrospective study of patients with relapsed/refractory HL or aggress...
Classical Hodgkin lymphoma (cHL) and non-Hodgkin lymphoma rarely develop in the same patient synchronously or metachronously. Through a series of biopsies, we report a unique case of diffuse large B-cell lymphoma (DLBCL) with stepwise development of classical Hodgkin lymphoma. An intermediate stage of transformation was identified with scattered Re...
IL-6 is critical for tumorigenesis. However, previous studies on the association of IL-6 promoter polymorphisms with predisposition to different cancer types are somewhat contradictory. Therefore, we performed this meta-analysis regarding the relationship between IL-6 promoter single nucleotide polymorphisms and cancer susceptibility and prognosis....
Citations
... Similarly, T-cell and putative Natural killercell neoplasms were sub-divided into Precursor T-cell neoplasm and Peripheral T-cell and NK-cell neoplasms (10). Murphy and Ann arbor staging schema stages lymphoma based on the number of lymph nodes or single extranodal organ or site involved (12). French-American-British/LMB system is specifically designed for classification of B-cell non-hodgkin lymphoma (13). ...
... Vorinostat, first FDA approved Histone deacetylase inhibitors were found to yield an enormous and profound outcomes in the lines of treatment planning and prognosis in groups of cutaneous T-cell lymphoma (17). Blockade of intracellular signalling by temsirolimus (mTOR inhibitor), (12). DIAGNOSIS: Lymph node biopsy is effective since FNAC exhibits low diagnostic yield (11). Staging is important for planning treatment, estimating prognosis and confirmation of working diagnosis. ...
Addressing health issues in paediatric population poses a major challenge to health care providers due to lack of child’s capability in expressing varied range of symptoms through which they undergo which may be of utmost diagnostic significance, thereby delaying early diagnosis. Unfortunately, Cancer is well known to be a common cause for increase in mortality rates in children. To achieve early diagnosis, careful attention to constellation symptoms portrayed by chid and/or parents suggestive of malignancy may aid in earlier diagnosis. With no disparity between early and late diagnosed cases, treatment modalities such as radio/chemotherapy and surgeries poses risk of recurrence, short and long term effects due to chemo/ radiation. To overcome all the aforementioned facts, new perspectives like targeted immunotherapy and Proton beam therapy proves beneficial and prevents children from emotional and physical trauma and primarily, from peer pressure. Updating with common head and cancers and advances in treatment may facilitate health care professionals in early diagnosis thereby, preventing disease progression. This article briefs about commonly occuring head and neck tumors in paediatrics, latest updates, advancements and an overview of impact of Global pandemic on current oncology practices with special concern on outcomes to be faced post pandemic.
Hematological malignancies(HMs) are highly heterogeneous diseases with globally rising incidence. Despite major improvements in the management of HMs, conventional therapies have limited efficacy, and relapses with high mortality rates are still frequent. Cordycepin, a nucleoside analog extracted from Cordyceps species, represents a wide range of therapeutic effects, including anti-inflammatory, anti-tumor, and anti-metastatic activities. Cordycepin induces apoptosis in different subtypes of HMs by triggering adenosine receptors, death receptors, and several vital signaling pathways such as MAPK, ERK, PI3K, AKT, and GSK-3β/β-catenin. This review article summarizes the impact of utilizing cordycepin on HMs, and highlights its potential as a promising avenue for future cancer research based on evidence from in vitro and in vivo studies, as well as clinical trials.
